In addition to Daniel, 9 other DHR executives reported Sell trades in the last month. Following Daniel’s last DHR Sell transaction on April 27, 2015, the stock climbed by 4.3%.
Based on Danaher Corp`s latest earnings report from June 30, the company posted quarterly revenue of $5.13B and quarterly net profit of $695.6M. In comparison, last year the company earned revenue of $4.96B and had a net profit of $676.4M. The company has a one year high of $90.11 and a one year low of $69.82. DHR’s market cap is $60B and the company has a P/E ratio of 24.2%.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $100.25, reflecting a -13.0% downside.
Looking at blogger coverage of DHR, there is a 83% Bullish tendency on the stock, in relation to a 66% average bullish tendency within the Conglomerates sector.
Over the last 3 months, the insider sentiment on Danaher Corp has been negative based on 64 corporate insider transactions. This sentiment is slightly lower than the average sector sentiment of insiders.
Danaher Corp designs, manufactures & markets professional, medical, industrial & commercial products. Its business consists of five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental & Industrial Technologies.